Case Reports  |   June 1996
Sensitivity to Mivacurium in a Patient with Mitochondrial Myopathy
Author Notes
  • (Naguib) Professor of Anaesthesia.
  • (El Dawlatly) Consultant Anaesthetist.
  • (Ashour) Associate Professor of Thoracic Surgery.
  • (Al-Bunyan) Associate Professor of Neurology.
  • Received from the Departments of Anaesthesiology, Thoracic Surgery, and Medicine, King Saud University Faculty of Medicine at King Khalid University Hospital, Riyadh, Saudi Arabia. Submitted for publication October 16, 1995. Accepted for publication January 29, 1996.
  • Address correspondence to Dr. Naguib: Department of Anaesthesiology and Intensive Care Unit, King Khalid University Hospital, P.O. Box 7805, Riyadh 11472, Saudi Arabia. Address electronic mail to: f35a002@saksu00.
Article Information
Case Reports / Endocrine and Metabolic Systems / Neuromuscular Diseases and Drugs
Case Reports   |   June 1996
Sensitivity to Mivacurium in a Patient with Mitochondrial Myopathy
Anesthesiology 6 1996, Vol.84, 1506-1509. doi:0000542-199606000-00029
Anesthesiology 6 1996, Vol.84, 1506-1509. doi:0000542-199606000-00029
THE mitochondrial myopathies are a clinically and biochemically heterogeneous group of disorders characterized by structural mitochondrial abnormalities on skeletal muscle biopsy. [1] The morphologic hallmark of mitochondrial myopathy is the ragged red fiber, [2] seen with the modified Gomori trichrome stain, containing peripheral and intermyofibrillar accumulations of abnormal mitochondria. In some cases, the fibers do not have a ragged appearance. Affected fibers also contain an excess of glycogen granules and increased numbers of fine neutral lipid droplets. [1] Both isolated myopathies and several multisystem syndromes have been identified. The syndromes, which are defined through characteristic clinical manifestations in addition to mitochondrial myopathy, are chronic progressive external ophthalmoplegia, including Kearns-Sayre syndrome, [3] MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) syndrome, [4] MERRF (myoclonus epilepsy and ragged red fibers) syndrome, [5] MNGIE (myopathy, external ophthalmoplegia, neuropathy, and gastrointestinal encephalopathy) syndrome, [6] and NARP (neuropathy, ataxia, and retinitis pigmentosa) syndrome. [7] .
Patients with mitochondrial myopathies have been reported to be sensitive to the effects of thiopental. [8] In addition, they are susceptible to develop atrioventricular conduction blocks, ranging from bundle-branch block to third-degree AV block. [9] Intrathecal administration of 10 mg hyperbaric tetracaine was reported to be safe in a patient with MELAS syndrome. [10] There are conflicting reports on the response of mitochondrial myopathy patients to the neuromuscular blocking drugs. [11–14] .
We report the anesthetic management of a patient with mitochondrial myopathy and the response to the nondepolarizing muscle relaxant mivacurium.
Case Report
A 16-yr-old boy, weighing 37 kg and 165 cm in height, with the diagnosis of mitochondrial myopathy was scheduled for surgical closure of tracheotomy stoma. Mitochondrial myopathy had been diagnosed 2 yr previously, at which time he was admitted to the hospital because of a 1-yr history of generalized fatigue and bilateral ptosis. At physical examination, he was slender, and neurologic examination revealed ptosis; restricted eye movements in lateral, medial, and upper directions; and mild proximal and distal muscle weakness. Nerve conduction study results were normal. Needle electromyography of tibialis anterior, quadriceps, biceps, and thenar muscles was suggestive of myopathic changes. Myasthenia gravis was suspected, but an edrophonium test was negative. Muscle biopsy from the rectus femoris muscle showed no evidence of ragged red fibers with the modified Gomori trichrome stain. ATPase reactions showed slight type II fiber predominance. Pulmonary function tests suggested a mild restrictive ventilatory impairment. The patient experienced increasing shortness of breath over a 3-wk period, which culminated in acute respiratory failure necessitating tracheal intubation and mechanical ventilation. Tracheotomy was performed 2 weeks later. Plasmapheresis was performed four times without improvement of the patient's conditions. Electron-microscopic studies confirmed the mitochondrial abnormalities in the muscle. It showed that the mitochondria were numerically increased, usually enlarged with disorganized cristae, and contained paracrystalline structures surrounded with an abundance of glycogen. Relevant laboratory results included negative antistriated muscle and acetylcholine receptor antibodies, normal creatine kinase, normal serum lactic acid, and normal thyroid function. Mechanical ventilation eventually was discontinued. The patient was discharged 4 months after his first admission.
The patient was readmitted 2 yr later for observation after removal of the tracheostomy tube. The stoma was covered with an airtight dressing. The patient was comfortable and breathing normally, and there were no harsh breath sounds or stridor. However, surgical closure of the stoma was planned because it had been in place 2 yr and had become lined by skin.
Preoperative physical examination revealed the features of mitochondrial myopathy mentioned earlier. The patient denied any recent history of weakness or fatigue. Of note was the diminished muscle bulk. The vital signs and results of laboratory tests were normal. The reported plasma cholinesterase activity was 13.1 units *symbol* ml sup -1 (reference range 7–19 units *symbol* ml sup -1). The dibucaine number was 80.7 (normal range 80–88), and the fluoride number was 49.1 (normal range 45–55). Abnormalities were found in the serum lactate concentration (3.2 mmol *symbol* l sup -1; normal range 0.5–2.2 mmol *symbol* l sup -1). Pulmonary function tests suggested a mild restrictive ventilatory impairment. Informed consent was taken to study the patient's response to mivacurium.
No premedication was given. An intravenous catheter for fluid and drug administration was inserted. The tracheostomy stoma was covered with an airtight dressing. A 20-G radial arterial cannula was inserted using local anesthesia before induction of general anesthesia. The electrocardiogram and invasive arterial pressure were monitored continuously. Hemoglobin oxygen saturation (SpO2) was monitored by pulse oximetry. Temperature was monitored by a nasopharyngeal thermistor and maintained between 35.5 degrees C and 37.5 degrees Celsius. Noninvasive temporary pacemaker electrodes (Cardio Aid, SW, Medico Teknik A-S, Albertoslaund, Denmark) were applied to the patient, and an infusion of isoproterenol was prepared.
Anesthesia was induced with incremental doses of propofol and maintained with 70% N2O in oxygen and a propofol infusion of 45–90 micro gram *symbol* kg sup -1 *symbol* min sup -1. The patient received no sedative or opioid. Topical anesthesia of the larynx and trachea was achieved by spraying 4 ml 4% lidocaine. The concentrations of nitrous oxide, oxygen, and carbon dioxide were measured continuously by a multiple-gas analyzer (Capnomac, Datex, Helsinki, Finland). Ventilation was adjusted to maintain normocapnia (end-tidal partial pressure of carbon dioxide 35–40 mmHg). The ulnar nerve was stimulated supramaximally at the wrist with square pulses of 0.2 ms duration, delivered in a train-of-four (TOF) sequence at 2 Hz every 12 s, using a Myotest peripheral nerve stimulator (Biometer, Odense, Denmark). The resultant contraction of the adductor pollicis muscle was recorded using a force displacement transducer and neuromuscular function analyzer (Myograph 2000, Biometer). Preload tension on the thumb was maintained at 300 g throughout the procedure.
Fade was initially present in the TOF response. After stabilization of twitch height, the TOF ratio (the amplitude of the fourth evoked response as a fraction of the first evoked response; T4/T1) was noted to be 0.59. Administration of 10 mg edrophonium did not produce any measurable effect on the TOF fade or on the T1 response (the first response in TOF). Ten minutes later, 15 micro gram *symbol* kg sup -1 mivacurium (10% of the commonly used dose) was administered over 5 s. The first measurable effect (lag time) and the maximum neuromuscular block (onset time) developed in 46 and 143 s, respectively. The maximum block attained was 98% inhibition of T1. Bronchoscopy was performed for evaluation of the upper airways. Thereafter, tracheal intubation was carried out, and the conditions were excellent.
The first twitch (T1) recovered to 10% of the control tension 575 s (9.6 min) after the administration of mivacurium. Recovery of T1 to 25%, 75%, 95%, and 100% of control took 12.9, 24.6, 36.3, and 38.3 min, respectively. At 100% recovery of T1, the TOF ratio was 0.54. Monitoring of the neuromuscular was continued for another 10 min, at which time TOF ratio had recovered to 0.60. Anesthesia was discontinued, the endotracheal tube was removed, and the patient was able to sustain a head-lift for 5 s and cough effectively. No abnormalities in cardiac rhythm were noted, and there was no need to use the external pacemaker. The patient was observed for 24 h in the intensive care unit and later was discharged to the ward. Vital signs were stable throughout the perioperative period. Postoperative neurologic examination showed no significant change. The patient made uneventful recovery and was discharged home after 2 days.
Our patient with mitochondrial myopathy demonstrated an extreme sensitivity to mivacurium, and despite appropriate dosing of the relaxant, recovery was prolonged. This finding is in marked contrast to that of D'Ambra et al., [14] who suggested that mitochondrial myopathy does not involve the neuromuscular junction. Mivacurium sensitivity is known to occur in patients with myasthenia gravis [15] or those with plasma cholinesterase deficiency. [16] The facial appearance of this patient and extreme sensitivity to mivacurium are similar to those seen in myasthenic patients. In this patient, however, myasthenia gravis had been ruled out by edrophonium test (both clinically and with mechanomyographic monitoring) and by the absence of an elevated titer of acetylcholine receptor antibodies. In addition, plasma cholinesterase activity, dibucaine, and fluoride numbers were within normal limits in this patient.
Hart et al. [17] demonstrated that administration of edrophonium during constant infusion of mivacurium (a situation different from the usual clinical practice) resulted in increase of concentrations of mivacurium's two potent stereoisomers, cis-trans and trans-trans. However, 8 min after antagonism, edrophonium's effect on mivacurium elimination had resolved. Plasma clearance of edrophonium in humans is rapid. Calvey et al. [18] reported that concentrations of edrophonium in plasma decreased from 7.82+/-2.95 nmol *symbol* ml sup -1 (mean+/-SE) to 1.75+/-0.15 nmol *symbol* ml sup -1 between 2 and 5 min. Edrophonium (10 mg (270 micro gram *symbol* kg sup -1)) was administered 10 min before the administration of mivacurium to our patient. The prior administration of edrophonium to this patient may have influenced the quality of mivacurium-induced blockade. All patients with similar presentations who receive mivacurium would not respond the same way.
Savarese et al. [19] reported that 30 micro gram *symbol* kg sup -1 mivacurium (ED10) produced 9.4%(SE 4.5%) inhibition of T1 in normal patients with a mean time to 95% recovery of T1 of 12.5 min (SE 2.5 min). In contrast, after administration of 15 micro gram *symbol* kg sup -1 mivacurium, which caused 98% block in our patient, the duration from injection to recovery of T1 to 95% of control force was 36.3 min. This patient was far more sensitive than previously described in myasthenics. Paterson et al. [14] noted in myasthenic patients that 30 micro gram *symbol* kg sup -1 mivacurium produced 37.5% twitch depression. We noted in myasthenic patients during nitrous oxide/oxygen/fentanyl anesthesia that the mean maximum depression of T1 after 20 micro gram *symbol* kg sup -1 mivacurium was 90% from control tension.* Furthermore, the nature of this patient's recovery from mivacurium-induced neuromuscular block was more prolonged than previously described in myasthenic patients. Gitlin et al. [20] found that a patient with myasthenia gravis who had received 0.15 mg *symbol* kg sup -1 mivacurium had recovered two twitches in response to the TOF stimulation within 10 min after the administration of the relaxant.
The response of patients with mitochondrial myopathy to neuromuscular blocking drugs is controversial. Robertson [11] described a 7-yr-old boy with ocular muscular dystrophy (a disorder associated with structurally and/or functionally abnormal mitochondria), who showed an extreme sensitivity to d-tubocurarine with lack of reversal by neostigmine. Others have used this sensitivity to investigate patients with ophthalmoplegia. [12] Further, Lessell et al. [13] reported an unusual sensitivity to succinylcholine in a 48-yr-old woman with progressive ocular myopathy. In contrast, D'Ambra et al. [14] suggested that mitochondrial myopathy did not involve the neuromuscular junction because their patient showed normal response to both pancuronium and succinylcholine.
The existence of a myopathy should raise concerns of malignant hyperthermia. Ohtani et al. [21] reported a case of malignant hyperthermia after succinylcholine in a patient with mitochondrial myopathy. This patient was treated promptly, but there were no details of subsequent in vitro test of muscle contractility specific for malignant hyperthermia. Therefore, one may wish to avoid known triggering drugs of malignant hyperthermia. Drugs that can trigger malignant hyperthermia (such as potent volatile anesthetics and succinylcholine) were avoided in our patients. We used nitrous oxide, propofol, and mivacurium, all of which have been reported to be safe in susceptible patients. [22] .
Decreased ventilatory responses to both hypoxia and hypercapnia (not related to respiratory muscle weakness) have been recognized as a part of spectrum of mitochondrial myopathy. [23] The decreased ventilatory response is of special significance to anesthesiologists because it may become apparent with opioids or other drugs that may impair regulation of breathing after surgical procedures. Therefore, we avoided sedatives and opioids in our patient.
Mitochondrial myopathies are a group of disorders with variable clinical manifestations and an underlying mitochondrial defect. We have described anesthetic management of a patient with mitochondrial myopathy who demonstrated an increased sensitivity to mivacurium. This sensitivity was not due to decreased plasma cholinesterase activity or myasthenia gravis. With reduced dosage and adequate monitoring of neuromuscular function, mivacurium can be used safely in the patient with mitochondrial myopathy. However, it is premature to make any generalizations from this report.
*Naguib M: Unpublished data. 1995.
Morgan-Hughes JA: Mitochondrial diseases, Skeletal Muscle Pathology. Edited by Mastaglia FL, Walton J. Edinburgh, Churchill Livingstone, 1992, pp 367-424.
Olson W, Engel WK, Walsh GO, Einaugler R: Oculocraniosomatic neuromuscular disease with ‘ragged-red’ fibres. Arch Neurol 1972; 26:193-211.
Kearns TP, Sayre GP: Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: Unusual syndrome with histologic study in one of two cases. Arch Ophthalmol 1958; 60:280-9.
Pavlakis S, Phillips PC, DiMauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Ann Neurol 1984; 16:481-8.
Fukuhara N, Tokiguchi S, Shirakawa K, Tsubaki T: Myoclonous epilepsy associated with ragged-red fibres (mitochondrial abnormalities): Disease entity or a syndrome? Light- and electron-microscopic studies of two cases and review of the literature. J Neurol Sci 1980; 47:117-33.
Hirano M, Silvestri G, Blake DM, Lombes A, Minetti C, Bonilla E, Hays AP, Lovelace RE, Butler I, Bertorini TE, Threlkeld AB, Mitsumoto H, Salberg LM, Rowland LP, DiMauro S: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994; 44:721-7.
Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA: A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46:428-33.
James RH: Thiopentone and ophthalmoplegia plus (letter). Anaesthesia 1985; 40:88.
Roberts NK, Perloff JK, Kark RAP: Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy): Report of 2 cases and review of 17 published cases. Am J Cardiol 1979; 44:1396-400.
Maslow A, Lisbon A: Anesthetic considerations in patients with mitochondrial dysfunction. Anesth Analg 1993; 76:884-6.
Robertson JA: Ocular muscular dystrophy: A cause of curare sensitivity. Anaesthesia 1984; 39:251-3.
Jacob JC, Varkey GP: Curare sensitivity in ocular myopathy. Can Anaesth Soc J 1966; 13:449-52.
Lessell S, Kuwabara T, Feldman RG: Myopathy and succinylcholine sensitivity. Am J Ophthalmol 1969; 68:789-96.
D'Ambra MN, Dedrick D, Savarese JJ: Kearns-Sayre syndrome and pancuronium-succinylcholine-induced neuromuscular blockade. ANESTHESIOLOGY 1979; 51:343-5.
Paterson IG, Hood JR, Russell SH, Weston MD, Hirsch NP: Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73:494-8.
Naguib M, El-Gammal M, Daoud W, Ammar A, Moukhtar H, Turkistani A: Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. ANESTHESIOLOGY 1995; 82:1288-92.
Hart PS, Wright PMC, Brown R, Lau M, Sharma ML, Miller RD, Gruenke L, Fisher DM: Edrophonium increases mivacurium concentrations during constant mivacurium infusion, and large doses minimally antagonize paralysis. ANESTHESIOLOGY 1995; 82:912-8.
Calvey TN, Williams NE, Muir KT, Barber HE: Plasma concentration of edrophonium in man. Clin Pharmacol Ther 1976; 19:813-20.
Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U): A short-acting nondepolarizing ester neuromuscular blocking drug. ANESTHESIOLOGY 1988; 68:723-32.
Gitlin MC, Jahr JS, Margolis MA, McCain J: Is mivacurium chloride effective in electroconvulsive therapy?: A report of four cases, including a patient with myasthenia gravis. Anesth Analg 1993; 77:392-4.
Ohtani Y, Miike T, Ishitsu T, Matsuda I, Tamari H: A case of malignant hyperthermia with mitochondrial dysfunction. Brain Dev 1985; 7:249.
Felipe MAN, Gottmann S, Khambatta HJ: Malignant Hyperthermia Current Concepts. Madrid, Normed, 1988, pp 11-8.
Carroll JE, Zwillich C, Weil JV, Brooke MH: Depressed ventilatory response in oculocraniosomatic neuromuscular disease. Neurology 1976; 26:140-6.